Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-09
2007-01-09
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S561000
Reexamination Certificate
active
10660090
ABSTRACT:
The efficacy of levodopa therapy in patients being treated for Parkinson's disease is enhanced by administering high doses of a partial glycine agonist. The frequency and severity of levodopa-induced side effects in Parkinson's disease patients are also reduced by administration of a partial glycine agonist.
REFERENCES:
patent: 4904681 (1990-02-01), Cordi et al.
patent: 5260324 (1993-11-01), Cordi et al.
patent: 5668117 (1997-09-01), Shapiro
patent: 6284776 (2001-09-01), Meltzer
patent: 6294583 (2001-09-01), Fogel
patent: 6417210 (2002-07-01), Melamed et al.
patent: 6551993 (2003-04-01), Schneider
patent: 2002/0035145 (2002-03-01), Tsai et al.
patent: WO 97/39797 (1997-04-01), None
patent: WO 99/52519 (1999-04-01), None
patent: WO 01/12190 (2001-02-01), None
Laake K. Oeksengaard AR, (2002) “D-cycloserine for Alzheimer's disease,”The Cochrane Library, Issue 4.
Wadie Najm, M.D. (2002), “Using Complementary Treatments in Dementia,”Center for clinical Age Management, Inc.
Sophie Erhardt, (2001), “Importance of endogenous kynurenic acid in brain catecholaminergic processes and in the pathophysiology of schizophrenia,”Doctor's Thesis from Karolinska Institutet91:628-4889-5.
V. Lelong et al., (2001), “RS 67333 and D-cycloserine accelerate learning acquisition in the Rat.,”Neuropharmacology41:517-522. (abstract only).
B.N.M. van Berckel et al., (1998), “original investigation: The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers,”Psychopharmacology-Abstract, 138:190-197. (abstract only).
P. Riekkinen Jr. et al., (1998), “D-cycloserine, a partial NMDA receptor-associated glycine-B site agonist, enchances reversal learning, but a cholinesterase inhibitor and nicotine has no effect,”NeuroReport, 9:3647-3651. (abstract only).
J.F. Disterhoft et al., (1997), “Mechanisms of associative learning in young and aging hippocampus,”Journal of Physiology, 501:6S.
Robert van Reekum, MD FRCPC et al., (1997), “Cognition-Enhancing Drugs in Dementia: A Guide to the Near Future,”Can J Psychiatry, 42:35S-50S.
J.W. Allen, B.S., (1996), “A Review of the Actions of D-cycloserine, a Putative Nootropic Agent, at the NMDA Receptor Complex-Associated Glycine Binding Site,”MJM, 2:40-50.
R.B. Rosse et al., (1996), “D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia,”Clin Neuropharmacol, 19:444-450. (abstract only).
M. Pitkanen et al., (1995), “The effects of d-cycloserine, a partial agonist at the glycine binding site, on spatial learning and working memory in scopolamine-treated rats,”J Neural Transm Park Dis Dement, 9:133-144. (abstract only).
“Treatment of Negative Symptoms in Schizophrenia,”Fiscal Year 2000 NIH GPRA Research Program Outcomes, p. 465. (abstract only).
(“Psychosis in Late Life, Ongoing Research,”Geriatric Consultant Resources LLC, accessed from: http://www.gcrweb.com/PsychosisDSS/clinical/pyalt.html on Jan. 16, 2003.
Donald Goff, M.D., “Glycine and D-Cycloserine in Schizophrenia,”NIMH Study ID No. MH57708study started 1998/completed 2002; record accessed on Jan. 16, 2003 from http://www.clinicaltrials.gov/show/NCT00000372 (abstract only).
Drinker Biddle & Reath LLP
Spivack Phyllis G.
Thomas Jefferson University
LandOfFree
Methods and kit for treating Parkinson's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and kit for treating Parkinson's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and kit for treating Parkinson's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3781506